The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for prevention trials, and measure subtle disease progression in the earliest stages of Alzheimer's disease, and will include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial, the Alzheimer's Prevention Initiative Generation Study, and the Anti-Amyloid Treatment in Asymptomatic Alzheimer's to compare current approaches and tools that are being developed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021264 | PMC |
| http://dx.doi.org/10.1016/j.trci.2018.01.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SARS-CoV-2 membrane protein induces neurodegeneration via affecting Golgi-mitochondria interaction.
Transl Neurodegener
December 2024
Department of Neurosciences, Hengyang Medical School, University of South China, Hengyang, 421009, China.
Background: Neurological complications are a significant concern of Coronavirus Disease 2019 (COVID-19). However, the pathogenic mechanism of neurological symptoms associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is poorly understood.
Methods: We used Drosophila as a model to systematically analyze SARS-CoV-2 genes encoding structural and accessory proteins and identified the membrane protein (M) that disrupted mitochondrial functions in vivo.
Therapeutic implications of necroptosis activation in Alzheimer´s disease.
Alzheimers Res Ther
December 2024
Laboratory of Neurodegenerative Diseases, Center for Biomedicine, Universidad Mayor, Temuco, Chile.
In recent years, a growing body of research has unveiled the involvement of the necroptosis pathway in the pathogenesis of Alzheimer's disease (AD). This evidence has shed light on the mechanisms underlying neuronal death in AD, positioning necroptosis at the forefront as a potential target for therapeutic intervention. This review provides an update on the current knowledge on this emerging, yet rapidly advancing topic, encompassing all published studies that present supporting proof of the role of the necroptosis pathway in the neurodegenerative processes of AD.
View Article and Find Full Text PDFEffects of missing data imputation methods on univariate blood pressure time series data analysis and forecasting with ARIMA and LSTM.
BMC Med Res Methodol
December 2024
School of Mathematical & Statistical Sciences, University of Texas Rio Grande Valley, One West University Boulevard, Brownsville, TX, 78520, USA.
Background: Missing observations within the univariate time series are common in real-life and cause analytical problems in the flow of the analysis. Imputation of missing values is an inevitable step in every incomplete univariate time series. Most of the existing studies focus on comparing the distributions of imputed data.
View Article and Find Full Text PDFHearing modulation affects Alzheimer's disease progression linked to brain inflammation: a study in mouse models.
Mol Med
December 2024
Department of Otolaryngology-Head and Neck Surgery, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jaebong-Ro, Dong-Gu, Gwangju, 61469, Republic of Korea.
Background: Recent studies have identified hearing loss (HL) as a primary risk factor for Alzheimer's disease (AD) onset. However, the mechanisms linking HL to AD are not fully understood. This study explored the effects of drug-induced hearing loss (DIHL) on the expression of proteins associated with AD progression in mouse models.
View Article and Find Full Text PDFHigher CSF sTREM2 attenuates APOE ε4-related risk for amyloid pathology in cognitively intact adults: The CABLE study.
J Neurochem
January 2025
Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
The triggering receptor expressed on myeloid cells 2 (TREM2) is a transmembrane protein found in microglia within the brain, and its soluble form (sTREM2) has been shown to reduce amyloid deposition. Whether elevated TREM2-mediated microglial activity decreases the risk of Alzheimer's disease (AD) is unclear. The aim of this study was to assess whether high cerebrospinal fluid (CSF) levels of sTREM2 attenuate the risk of APOE ε4-associated amyloid pathology.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!